Search research articles
Contact Us
Filters
Showing results (51-60 of 133) with videos related to
Page
of 14
Sort By:
Journal of Clinical Pharmacology
|
February 5, 2015
Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches
David S Small, Alice Ban Ke, Stephen D Hall, et al.
Scientific Reports
|
November 26, 2024
Characterising the inconsistency between perceived and actual sleep and its impact upon cognition and mood
Hannah Windmill, Alexander Dyer, Alastair D Smith, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 31, 2023
Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4
Luc R A Rougée, David W Bedwell, Kasi Hansen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 4, 2009
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin
Sara K Quinney, Xin Zhang, Aroonrut Lucksiri, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 25, 2008
Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes
Jennifer B Dennison, Michael A Mohutsky, Robert J Barbuch, et al.
Frontiers in Human Neuroscience
|
April 19, 2013
A multimodal perspective on the composition of cortical oscillations
Kim C Ronnqvist, Craig J McAllister, Gavin L Woodhall, et al.
Therapeutic Drug Monitoring
|
June 4, 2008
Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry
Jennifer B Dennison, Jamie L Renbarger, David O Walterhouse, et al.
Frontiers in Neurology
|
January 11, 2020
Bradykinesia Is Driven by Cumulative Beta Power During Continuous Movement and Alleviated by Gabaergic Modulation in Parkinson's Disease
Emma J Prokic, Ian M Stanford, Gavin L Woodhall, et al.
Clinical Pharmacology and Therapeutics
|
July 30, 2019
Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions
Yingying Guo, Aroonrut Lucksiri, Gemma L Dickinson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
April 12, 2005
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance
Silvana Borges, Lang Li, Mitchell A Hamman, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 133) with videos related to
Sort By:
Page
of 14
Journal of Clinical Pharmacology
|
February 5, 2015
Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches
David S Small, Alice Ban Ke, Stephen D Hall, et al.
Scientific Reports
|
November 26, 2024
Characterising the inconsistency between perceived and actual sleep and its impact upon cognition and mood
Hannah Windmill, Alexander Dyer, Alastair D Smith, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 31, 2023
Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4
Luc R A Rougée, David W Bedwell, Kasi Hansen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 4, 2009
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin
Sara K Quinney, Xin Zhang, Aroonrut Lucksiri, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 25, 2008
Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes
Jennifer B Dennison, Michael A Mohutsky, Robert J Barbuch, et al.
Frontiers in Human Neuroscience
|
April 19, 2013
A multimodal perspective on the composition of cortical oscillations
Kim C Ronnqvist, Craig J McAllister, Gavin L Woodhall, et al.
Therapeutic Drug Monitoring
|
June 4, 2008
Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry
Jennifer B Dennison, Jamie L Renbarger, David O Walterhouse, et al.
Frontiers in Neurology
|
January 11, 2020
Bradykinesia Is Driven by Cumulative Beta Power During Continuous Movement and Alleviated by Gabaergic Modulation in Parkinson's Disease
Emma J Prokic, Ian M Stanford, Gavin L Woodhall, et al.
Clinical Pharmacology and Therapeutics
|
July 30, 2019
Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions
Yingying Guo, Aroonrut Lucksiri, Gemma L Dickinson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
April 12, 2005
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance
Silvana Borges, Lang Li, Mitchell A Hamman, et al.
Page
of 14